Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

@article{Hammer2013EfficacyTO,
  title={Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.},
  author={Scott M. Hammer and Magdalena E. Sobieszczyk and Holly E Janes and Shelly Tanner Karuna and Mark Mulligan and Doug Grove and Beryl A Koblin and Susan P Buchbinder and Michael C. Keefer and Georgia D. Tomaras and Nicole Frahm and John A Hural and Chuka Anude and Barney S. Graham and Mary E. Enama and Elizabeth E. Adams and Edwin Dejesus and Richard M Novak and Ian Frank and Carter Bentley and Shelly Ramirez and Rong Fu and Richard A. Koup and John R. Mascola and Gary J. Nabel and David C. Montefiori and James G. Kublin and M Juliana McElrath and Lawrence Corey and Peter B. Gilbert},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 22},
  pages={2083-92}
}
BACKGROUND A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States. METHODS At 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive the DNA/rAd5 vaccine (1253 participants) or placebo (1251 participants). We… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS